Modified T Cell Therapy for Non-Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

+27 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests JCAR017, a therapy that modifies a patient's immune cells to fight cancer, in adults with difficult-to-treat non-Hodgkin's lymphoma. The study aims to find the safest and most effective way to use this therapy. JCAR017 has shown potential in treating non-Hodgkin's lymphoma.

Eligibility Criteria

Adults over 18 with B-cell non-Hodgkin's lymphoma that has returned or didn't respond to treatment can join. They must have had at least two prior treatments, be in good health overall, and not pregnant. People who've had certain recent cancer therapies or infections, other cancers within the last two years (with some exceptions), or active hepatitis or HIV are excluded.

Inclusion Criteria

My PET scan shows active cancer.

I have a specific type of B-cell lymphoma and my previous treatments, including anthracycline and rituximab, did not work.

I have MCL that has not improved after at least 2 treatments, including specific drugs.

See 7 more

Exclusion Criteria

I have been cancer-free for at least 2 years, except for certain low-risk types.

I do not have any untreated serious infections.

I have graft-vs-host disease.

See 18 more

Treatment Details

Interventions

JCAR017 (lisocabtagene maraleucel) 2-dose schedule (CAR T-cell Therapy)
JCAR017 (lisocabtagene maraleucel) single-dose schedule (CAR T-cell Therapy)

Trial OverviewThe trial is testing JCAR017, a modified T cell therapy for lymphoma. Patients will receive either one dose or a two-dose schedule of this treatment to see how safe it is and how well it works against their cancer.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: JCAR017 2-dose schedule (no longer accruing)Experimental Treatment1 Intervention

Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections

Group II: JCAR017 1-dose scheduleExperimental Treatment1 Intervention

Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection